ENTITY
iX Biopharma

iX Biopharma (IXBIO SP)

5
Analysis
Health Care • Singapore
iX Biopharma is a specialty pharmaceutical and nutraceutical company that develops and commercializes innovative therapies for pain and other health conditions, leveraging proprietary sublingual drug delivery technologies such as WaferiX and WaferlogiX. Key products in development include Wafermine (ketamine wafer) for pain and BnoX (buprenorphine). The company was founded in Singapore in 2008.
more
bullish•iX Biopharma
•03 Mar 2026 00:00•Exchange-sponsored

Liquidity & Capital: Institutional Participation Continues to Broaden across SGX

Institutions net bought Industrials, Real Estate, Telecommunications, Consumer Cyclicals, Technology, Consumer Non-Cyclicals, and Materials &...

Share
bullish•iX Biopharma
•09 Nov 2025 22:18

Primer: iX Biopharma Ltd (IXBIO SP) - Nov 2025

iX Biopharma is a specialty pharmaceutical company centered around its proprietary WaferiX sublingual drug delivery technology, which aims to...

Logo
295 Views
Share
bullish•ISDN
•29 Sep 2026 00:00•Exchange-sponsored

Net Institutional Inflow Reversals into Late September

Institutional investors recorded a net outflow of S$336 million across Singapore-listed stocks from 31 August to 25 September. Yangzijiang...

Share
bullish•Aztech Global
•04 Aug 2026 00:00•Exchange-sponsored

LGI Accumulates Shares in Valuetronics & iX Biopharma

Over five sessions, directors reported four acquisitions, substantial shareholders recorded five acquisitions and one disposal for 30...

Share
bullish•iX Biopharma
•14 Dec 2021 08:00•Exchange-sponsored

(Non-SGX Report) IX Biopharma Ltd - Wafermine Out-Licensed for C.US$248m

Non- SGX Report: These equity research reports are not written by the SGX. SGX supports the distribution of the research reports by external...

Share
x